5-Aminolevulinic acid-induced protoporphyrin IX fluorescence in meningioma: Qualitative and quantitative measurements in Vivo

Neurosurgery

Volumn 10, Issue 1, 1982, Pages 74-82

  Valdes, Pablo A ^a,b,c   Bekelis, Kimon ^a   Harris, Brent T ^d   Wilson, Brian C ^e   Leblond, Frederic ^b,f   Kim, Anthony ^e   Simmons, Nathan E ^a   Erkmen, Kadir ^a   Paulsen, Keith D ^a,b   Roberts, David W ^a,c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH COLLEGE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

Author keywords

5 Aminolevulinic acid; Biophotonics; Brain tumor; Fluorescence guided surgery; Meningioma Optical spectroscopy; Protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID; PROTOPORPHYRIN; DIAGNOSTIC AGENT; FLUORESCENT DYE; GADOLINIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DURA MATER; FEMALE; FLUORESCENCE; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURGICAL MICROSCOPE; ANALYSIS OF VARIANCE; CANCER STAGING; CLUSTER ANALYSIS; LIGHT; METABOLISM; NEUROSURGERY; VERY ELDERLY; CANCER SURGERY; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; DESCRIPTIVE RESEARCH; DIAGNOSTIC TEST ACCURACY STUDY; FIBROMA; IN VIVO STUDY; INTRAOPERATIVE PERIOD; NEURONAVIGATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; ANALYSIS OF VARIANCE; CLUSTER ANALYSIS; FEMALE; FLUORESCENCE; FLUORESCENT DYES; HUMANS; LIGHT; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM STAGING; NEUROSURGICAL PROCEDURES; PROSPECTIVE STUDIES; PROTOPORPHYRINS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84907867658     PISSN: 0148396X     EISSN: 15244040     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000117     Document Type: Article

References (55)

1. DeAngelis LM. Brain tumors. N Engl J Med. 2001; 344 (2) : 114-123.
2. Bulsara KR, Al-Mefty O. Skull base surgery for benign skull base tumors. J Neurooncol. 2004; 69 (1-3) : 181-189.
3. Samii M, Gerganov VM. Surgery of extra-axial tumors of the cerebral base. Neurosurgery. 2008; 62 (6 suppl 3) : 1153-1166.
4. Nabavi A, Thurm H, Zountsas B, et al. Five-aminolevulinic acid for fluorescenceguided resection of recurrent malignant gliomas: A phase ii study. Neurosurgery. 2009; 65 (6) : 1070-1076; discussion 1076-1077.
5. Bekelis K, Valdés PA, Erkmen K, et al. Quantitative and qualitative 5-aminolevulinic acid-induced Protoporphyrin IX fluorescence in skull base meningiomas. Neurosurg Focus. 2011; 30 (5) : E8.
6. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescenceguided resection of glioblastoma multiforme by using 5-aminolevulinic acidinduced porphyrins: A prospective study in 52 consecutive patients. J Neurosurg. 2000; 93 (6) : 1003-1013.
7. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7 (5) : 392-401.
8. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery. 2008; 62 (3) : 564-576; discussion 564-576.
9. Valdes PA, Kim A, Brantsch M, et al. d-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: The need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro Oncol. 2011; 13 (8) : 846-856.
10. Valdés PA, Leblond F, Kim A, et al. Quantitative fluorescence in intracranial tumor: Implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg. 2011; 115 (1) : 11-17.
11. Roberts DW, Valdés PA, Harris BT, et al. Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid) . Neurosurg Clin N Am. 2012; 23 (3) : 371-377.
12. Valdes PA, Jacobs VL, Paulsen KD, Roberts DW, Leblond F. In vivo fluorescence detection in surgery: A review of principles, methods, and applications. Curr Med Imaging Rev. 2012; 8 (3) : 211-232.
13. Pogue BW, Gibbs-Strauss S, Valdés PA, Samkoe K, Roberts DW, Paulsen KD. Review of neurosurgical fluorescence imaging methodologies. IEEE J Sel Top Quantum Electron. 2010; 16 (3) : 493-505.
14. StummerW, Stepp H, Möller G, Ehrhardt A, Leonhard M, Reulen HJ. Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien) . 1998; 140 (10) : 995-1000.
15. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H. Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien) . 2010; 152 (10) : 1711-1719.
16. Kajimoto Y, Kuroiwa T, Miyatake S, et al. Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. J Neurosurg. 2007; 106 (6) : 1070-1074.
17. Morofuji Y, Matsuo T, Hayashi Y, Suyama K, Nagata I. Usefulness of intraoperative photodynamic diagnosis using 5-aminolevulinic acid for meningiomas with cranial invasion: Technical case report. Neurosurgery. 2008; 62 (3 suppl 1) : 102-103.
18. Tsai JC, Hsiao YY, Teng LJ, Chen CT, Kao MC. Comparative study on the ALA photodynamic effects of human glioma and meningioma cells. Lasers Surg Med. 1999; 24 (4) : 296-305.
19. Hefti M. Comment concerning: Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas, Acta Neurochir DOl 1O.1007/s00701-010-0708-4, Intratumoral heterogeneity and fluorescence intensity in meningioma after 5-ALA pretreatment. Acta Neurochir (Wien) . 2011; 153 (4) : 959-960.
20. Whitson WJ, Valdes PA, Harris BT, Paulsen KD, Roberts DW. Confocal microscopy for the histological fluorescence pattern of a recurrent atypical meningioma: Case report. Neurosurgery. 2011; 68 (6) : E1768-E1772; discussion E1772-E1773.
21. Kim A, Khurana M, Moriyama Y, Wilson BC. Quantification of in vivo fluorescence decoupled from the effects of tissue optical properties using fiber-optic spectroscopy measurements. J Biomed Opt. 2010; 15 (6) : 067006.
22. Valdés PA, Kim A, Leblond F, et al. Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery. J Biomed Opt. 2011; 16 (11) : 116007.
23. Valdés PA, Leblond F, Kim A,Wilson BC, Paulsen KD, Roberts DW. A spectrally constrained dual-band normalization technique for protoporphyrin IX quantification in fluorescence-guided surgery. Opt Lett. 2012; 37 (11) : 1817-1819.
24. Roberts DW, Valdés PA, Harris BT, et al. Coregistered fluorescence-enhanced tumor resection of malignant glioma: Relationships between d-aminolevulinic acidinduced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg. 2011; 114 (3) : 595-603.
25. Valdés PA, Leblond F, Jacobs VL, Wilson BC, Paulsen KD, Roberts DW. Quantitative, spectrally-resolved intraoperative fluorescence imaging. Sci Rep. 2012; 2: 798.
26. Kim A, Roy M, Dadani F, Wilson BC. A fiberoptic reflectance probe with multiple source-collector separations to increase the dynamic range of derived tissue optical absorption and scattering coefficients. Opt Express. 2010; 18 (6) : 5580-5594.
27. Bradley RS, Thorniley MS. A review of attenuation correction techniques for tissue fluorescence. J R Soc Interface. 2006; 3 (6) : 1-13.
28. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114 (2) : 97-109.
29. Stummer W, Stocker S, Wagner S, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery. 1998; 42 (3) : 518-525; discussion 525-526.
30. Shapiro DE. The interpretation of diagnostic tests. Stat Methods Med Res. 1999; 8 (2) : 113-134.
31. Buetow MP, Buetow PC, Smirniotopoulos JG. Typical, atypical, and misleading features in meningioma. Radiographics. 1991; 11 (6) : 1087-1106.
32. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene. 2011; 30 (20) : 2333-2344.
33. Jääskeläinen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: Radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986; 25 (3) : 233-242.
34. Ayerbe J, Lobato RD, de la Cruz J, et al. Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien) . 1999; 141 (9) : 921-932.
35. Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol. 1986; 26 (5) : 461-469.
36. Nakasu S, Nakasu Y, Nakajima M, Matsuda M, Handa J. Preoperative identification of meningiomas that are highly likely to recur. J Neurosurg. 1999; 90 (3) : 455-462.
37. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M. Malignant progression in meningioma: Documentation of a series and analysis of cytogenetic findings. J Neurosurg. 2004; 101 (2) : 210-218.
38. Borovich B, Doron Y. Recurrence of intracranial meningiomas: The role played by regional multicentricity. J Neurosurg. 1986; 64 (1) : 58-63.
39. Kinjo T, al-Mefty O, Kanaan I. Grade zero removal of supratentorial convexity meningiomas. Neurosurgery. 1993; 33 (3) : 394-399.
40. Kawahara Y, Niiro M, Yokoyama S, Kuratsu J. Dural congestion accompanying meningioma invasion into vessels: The dural tail sign. Neuroradiology. 2001; 43 (6) : 462-465.
41. Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: A review. J Neurooncol. 1996; 29 (3) : 197-205.
42. Chen TC, Zee CS, Miller CA, et al. Magnetic resonance imaging and pathological correlates of meningiomas. Neurosurgery. 1992; 31 (6) : 1015-1021; discussion 1021-1022.
43. Maiuri F, Iaconetta G, de Divitiis O, Cirillo S, Di Salle F, De Caro ML. Intracranial meningiomas: Correlations between MR imaging and histology. Eur J Radiol. 1999; 31 (1) : 69-75.
44. Ildan F, Tuna M, Göçer AP, et al. Correlation of the relationships of brain-tumor interfaces, magnetic resonance imaging, and angiographic findings to predict cleavage of meningiomas. J Neurosurg. 1999; 91 (3) : 384-390.
45. Elster AD, Challa VR, Gilbert TH, Richardson DN, Contento JC. Meningiomas: MR and histopathologic features. Radiology. 1989; 170 (3 pt 1) : 857-862.
46. Carpeggiani P, Crisi G, Trevisan C. MRI of intracranial meningiomas: Correlations with histology and physical consistency. Neuroradiology. 1993; 35 (7) : 532-536.
47. Kendall B, Pullicino P. Comparison of consistency of meningiomas and CT appearances. Neuroradiology. 1979; 18 (4) : 173-176.
48. Valdés PA, Fan X, Ji S, Harris BT, Paulsen KD, Roberts DW. Estimation of brain deformation for volumetric image updating in protoporphyrin IX fluorescenceguided resection. Stereotact Funct Neurosurg. 2010; 88 (1) : 1-10.
49. Valdés PA, Moses ZB, Kim A, et al. Gadolinium- and 5-aminolevulinic acidinduced protoporphyrin IX levels in human gliomas: An ex vivo quantitative study to correlate protoporphyrin IX levels and blood-brain barrier breakdown. J Neuropathol Exp Neurol. 2012; 71 (9) : 806-813.
50. Collaud S, Juzeniene A, Moan J, Lange N. On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents. 2004; 4 (3) : 301-316.
51. Curnow A, Pye A. Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors. J Environ Pathol Toxicol Oncol. 2007; 26 (2) : 89-103.
52. Valdés PA, Samkoe K, O'Hara JA, Roberts DW, Paulsen KD, Pogue BW. Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model. Photochem Photobiol. 2010; 86 (2) : 471-475.
53. Hefti M, Holenstein F, Albert I, Looser H, Luginbuehl V. Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity. Photochem Photobiol. 2011; 87 (1) : 235-241.
54. Blake E, Allen J, Curnow A. An in vitro comparison of the effects of the ironchelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection. Photochem Photobiol. 2011; 87 (6) : 1419-1426.
55. Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med. 1997; 16 (9) : 981-991.